secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2026-08-11T12:00:14+00:00
Accession:  0001193125-26-343469
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Q2 2026 net loss narrows to $13.9M; cash runway into Q2 2028
--------------------------------------------------------------------------------

- Q2 2026 net loss $13.9M ($0.14/share) vs $31.2M ($0.41/share) in Q2 2025.
- Cash, equivalents, restricted cash and marketable securities $155.2M at June 30, 2026; funds ops into Q2 2028.
- R&D expense fell to $16.1M from $25.8M YoY; G&A to $5.0M from $6.4M.
- Plan to initiate Phase 1 of PRT13722 (KAT6A degrader) in HR+ breast cancer in Q4 2026, pending IND.
- Enrollment continues for PRT12396 JAK2V617F inhibitor; mCALR DAC program advancing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/0001193125-26-343469-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526343469/prld-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-343469

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer